Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed...
By Avalon Pernell · Bloomberg
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range.